Can I get tested after one loss?

This is the page we most want you to have. If you've had a loss and someone told you to just try again, here's what the testing actually is, when you already qualify for it, and why finding out before your next pregnancy can matter more than finding out after.

First: a threshold is not a permission slip

Guidelines set the point at which an evaluation should be offered to you. They do not set the point at which you're allowed to ask. Those are different things, and the difference is where a lot of women lose a year.

Under current ASRM guidance, recurrent pregnancy loss means two or more losses — and they no longer have to be consecutive, and very early losses confirmed by a blood or urine test count. So if you've had two losses at any point, even with a healthy pregnancy between them, even if one was a chemical pregnancy, you meet the definition. A lot of women are told they don't when they do.

What's actually on the panel

There's no single universal "recurrent loss panel" — labs and clinics bundle it differently, which is exactly why it helps to know the pieces by name.

• Strong evidence Chromosome testing of the pregnancy tissue. Current guidance puts this first, using newer methods (SNP microarray, aCGH, or next-generation sequencing) rather than old-style karyotyping. It answers the biggest question: was this a random chromosomal event, or something that might repeat? This one is time-sensitive. If tissue isn't collected and sent, the window closes and that loss can never be explained.
• Strong evidence Antiphospholipid antibodies. Three tests: lupus anticoagulant, anticardiolipin (IgG and IgM), and anti-β2-glycoprotein I (IgG and IgM). This is a treatable clotting-related immune condition, and it's the one most often skipped. One caveat: the lupus anticoagulant test is unreliable during pregnancy or on blood thinners, so testing between pregnancies gives the clearest answer.
• Strong evidence Uterine cavity evaluation. A 3D ultrasound or saline sonohysterogram, recommended for anyone with unexplained recurrent loss. Looks for a septum, polyps, fibroids or scarring — several of which are fixable.
• Moderate evidence Thyroid (TSH), and diabetes screening (HbA1c) where there are risk factors, or where a miscarriage was chromosomally normal. Both are treatable and cheap to check.
• Moderate evidence Parental karyotype, recommended when tissue testing shows an unbalanced rearrangement — rather than for everyone up front.
• Emerging evidence Chronic endometritis (endometrial biopsy) and sperm DNA fragmentation are in the current guidance as reasonable in the right circumstances. Ask whether they apply to you specifically.

Why knowing before you try again changes things

This is the argument to make if you're told to wait, and it's the strongest one you have.

• Strong evidence APS cannot be diagnosed from one blood draw. A positive result has to be confirmed on a repeat test at least 12 weeks later, to prove the antibodies are persistent rather than a passing blip. Start that clock now and you can have an answer before you conceive. Start it after your next positive test and you're twelve weeks into a pregnancy waiting for a result that should already have changed your care.
• Moderate evidence The treatment starts early. For confirmed APS, the standard is low-dose aspirin plus prophylactic heparin, begun in early pregnancy and continued throughout. You cannot apply it retroactively. A diagnosis that arrives after a loss is a diagnosis that arrived a pregnancy too late.
• Tissue testing is time-sensitive. It's easiest when tissue is collected at the time of the loss. If tissue was already sent to pathology, ask whether a preserved sample was kept — it can sometimes be tested later. Waiting for a second loss to "qualify" can mean the first one goes unexplained.
• Moderate evidence Some findings are just fixable. A uterine septum, hypothyroidism, uncontrolled blood sugar — these get treated between pregnancies, not during one.

Where the evidence is genuinely contested

This is the part most patient resources skip, and skipping it does real harm. Some things aren't simply supported or unsupported — they're the subject of an active disagreement between what large trials have shown and what experienced specialists see in their own practice. You deserve to know which is which, because "not recommended" and "doesn't work for you" are very different statements.

• Emerging evidence Treating on the basis of antibodies that don't quite meet the criteria. The formal APS criteria are deliberately strict, and a great many women with recurrent loss have positive antibodies without satisfying them. There's a recognized category for this, real published outcome data, and a genuine split in practice. It's the single most important thing to understand if any of your antibody results have ever come back positive. What "non-criteria APS" means, and why a negative result outside pregnancy doesn't close the question →
• Insufficient evidence MTHFR variants — and the test that's actually more useful. The American College of Medical Genetics says MTHFR testing "has minimal clinical utility and therefore should not be ordered as part of a routine evaluation for thrombophilia," because the genotype on its own doesn't reliably predict anything. But the same guideline notes a modest increase in recurrent loss risk for people homozygous for the C677T variant who also have elevated homocysteine, and recommends measuring fasting homocysteine in those people. So the useful question isn't your genotype, it's your homocysteine level — and if you've already been tested and you're homozygous, asking for that number is a reasonable, guideline-consistent next step. Either folic acid or methylfolate is fine; neither has been shown to prevent loss better than the other.
• Safety consideration Aspirin and low-molecular-weight heparin when APS isn't confirmed. Here the scope of the evidence matters enormously, and it's almost always reported wrong. The trials that found anticoagulation didn't help studied women without APS — ALIFE enrolled unexplained recurrent miscarriage, and ALIFE2 enrolled inherited thrombophilia and explicitly excluded antiphospholipid syndrome. Those results are real and they're the reason guidelines are cautious. They are also not about women with positive antiphospholipid antibodies, for whom aspirin plus heparin is the established treatment. If your antibodies are positive, "heparin doesn't work" is a conclusion drawn from a population you're not in. That doesn't automatically make treatment right for you — it's injections, bruising, real cost, and bleeding risk to plan around at delivery — but it does mean the question is open and worth a specialist conversation rather than a flat no.

Be skeptical of these, even when a clinic offers them

And then there's the part where we're not going to pretend every test is worth your money. These are recommended against, they're frequently sold anyway, and some carry real risk:

• Insufficient evidence NK cell testing and immune therapies including IVIG, intralipids and steroids, outside of APS. Expensive, often thousands of dollars, and not supported.
• Insufficient evidence ERA (endometrial receptivity array) and endometrial microbiome testing. Not recommended.
• Insufficient evidence Large "reproductive immunology" panels sold as a bundle. Ask which guideline supports each component. A good clinic will have a straight answer for every line item, and a bundle that can't be itemized is a sales product.

The distinction that matters: the tests above have been studied and haven't held up. That is a different situation from a test whose result is positive but doesn't fit neatly into a classification box — which is a question about you, not a verdict about the science.

If a doctor and a specialist disagree about you

This happens constantly in recurrent loss, more than in almost any other area, because the guidelines are cautious by design and individual specialists see patterns across hundreds of cases that a guideline can't capture. Neither of them is being unreasonable. But you are the one who has to decide, often with ten minutes and no context.

• Ask each of them what the other might be seeing. "What would someone who disagreed with you say, and why do you think they're wrong?" A clinician who can't answer that hasn't thought about it.
• Ask whether the evidence they're citing includes people like you. This is the question that unlocks the anticoagulation debate specifically. "Were women with positive antibodies included in those studies?"
• Ask what the downside of being wrong is, in each direction. The cost of unnecessary treatment and the cost of a missed diagnosis are rarely equal, and rarely discussed.
• Get the reasoning in writing from whoever recommends a protocol, before you need it. A one-paragraph letter from the prescribing specialist ends most of these disputes before they start. More on what to do when two doctors disagree →

How to ask for it

Say it plainly. You do not need to apologize for wanting information.

That last sentence does more work than any other. It's not a demand, it turns a "no" into a reason, and a reason is something you can take to a second opinion.

If you're told no

• Ask for the reason in your chart. "Can you note in my record that I requested this and it wasn't ordered?" This is a completely reasonable request, and it tends to focus the conversation.
• Ask what would change the answer. Another loss? A later loss? A specific history? Now you know the trigger.
• Ask about the tissue plan. Even a doctor who won't run bloodwork today should agree on a plan to test the tissue if it happens again. Get that agreed in advance, because in the moment nobody is thinking about lab logistics.
• Consider a different specialist. Reproductive endocrinologists and maternal-fetal medicine doctors see recurrent loss all day; a general OB may see it rarely. See how to research a doctor.

And the thing we most want you to hold onto

Most women with recurrent loss — including those whose testing finds nothing at all — go on to have a successful pregnancy. Testing isn't about bracing for bad news. It's about walking into your next pregnancy knowing what's true, and having done everything that could be done.